Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

(Reuters) - Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

from Reuters: Health News https://ift.tt/2zfkZKb
via IFTTT